An experimental bird flu vaccine just saw success in trial — here's when it could be used to save poultry
The University of Buffalo researchers say that their process could be critical for the nation's response to bird flu strains as they mutate and continue to sicken humans, infect dairy cows, lead to the killing of millions of poultry birds and contribute to painful nationwide egg shortages.
'We obviously have a lot more work to do, but the results thus far are extremely encouraging,' Dr. Jonathan Lovell, a professor in the Department of Biomedical Engineering, said in a statement.
Lovell is the lead author of the associated study published Thursday in the journal Cell Biomaterials.
The work focused on the H5N1 variant known as 2.3.4.4b, which has caused widespread outbreaks in wild birds and poultry, in addition to infecting dairy cattle, house cats, sea lions, and other mammals.
In their research, the scientists developed a process for creating the experimental vaccine by focusing on two key proteins that help form the virus — both H5 and N1. The process was called a 'vaccine platform,' which Lovell says could set the vaccine apart from other bird flu vaccines currently approved for human use and help to tackle future and stronger strains.
The process adds the building blocks of proteins that are known as 'his-tags' to H5 and N1. It combines the his-tags and proteins with tiny sacs made of cobalt, the organic compound porphyrin, and an essential component of cell membranes. Then, they add adjuvants, which are ingredients used to ramp up vaccine strength.
The result is what's known as a 'recombinant protein vaccine.' It's made without live or dead versions of H5N1, relying on bits of genetic material from the virus to trigger the mouse's immune response.
While standard influenza shots are manufactured using virus grown in eggs, recombinant shots are egg-free.
'Because our vaccine does not require the use of eggs in the manufacturing process — as many influenza vaccines do — it is potentially a faster and more efficient way to protect humans and animals from deadly strains of bird flu,' Lovell said.
To test the vaccine, they used doses that contained H5 and N1 alone and the two proteins combined. They found that targeting H5 alone provided complete protection, while N1 gave partial protection. Those that contained both proteins also provided complete protection, but did not outperform H5 by itself.
Lovell says those results show the important role that the H5 protein plays in developing immunity to bird flu. H5 doses help the body remember and destroy the intruder. Whereas, N1 doses reduce the severity of illness.
The team plans to work more on the vaccine candidate, testing different doses and conditions.
'These bivalent formulations could be extremely advantageous as H5N1 evolves,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
a day ago
- Newsweek
Top Scientist Issues Stark mRNA Vaccine Warning to U.S.
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Rick Bright, the former director of the Biomedical Advanced Research and Development Authority (BARDA) has warned that Department of Health and Human Services' decision to cut funding for mRNA vaccine development could threaten American national security. "BARDA wasn't the only government agency making early investments in mRNA research," Bright wrote in an opinion piece for The New York Times. "The Department of Defense and the Defense Advanced Research Projects Agency had already recognized mRNA's potential for swift action against emerging biological threats, including those that might be weaponized." It comes after HHS Secretary Robert F. Kennedy Jr. announced the termination of 22 mRNA development investments and the reallocation of roughly $500 million at the beginning of this month. Why it Matters Bright said the mRNA platform had been central to the fast response to COVID-19 and that abandoning the technology would undermine the nation's ability to respond quickly to future biological threats. Multiple scientists and doctors have spoken out against this decision, including infectious diseases expert Dr. Thomas A. Russo, who told Newsweek that mRNA vaccines "will be critical when the next, inevitable infectious diseases crisis rears its ugly head." What To Know On August 5, the HHS confirmed it would cancel $500 million in mRNA vaccine development contracts, impacting research teams and proposals—including those from Emory University, Tiba Biotech, Pfizer, Sanofi Pasteur and others. The projects reportedly targeted respiratory viruses including seasonal influenza, COVID-19, RSV and H5N1 and included work by major industry and academic teams. Secretary Kennedy argued that the data showed mRNA vaccines had not met expectations for preventing upper respiratory infections and that HHS would shift funding toward other vaccine platforms. But Bright praised mRNA technology, saying that the "unprecedented speed" with which a COVID-19 vaccine was developed in 2020 "was possible only because years earlier, the United States had invested" in it. "This decision undercuts one of the most significant medical advances in decades, technology that could protect millions more people from the threats ahead," Bright said. "I know the stakes because I was BARDA's director when the United States made the decision to invest heavily in mRNA," he said. "That investment did not begin with Covid-19. It began in 2016, when we faced the Zika virus outbreak." "We needed a way to design a vaccine in days, not years, to protect pregnant women and their babies from devastating birth defects. Older vaccine approaches were too slow," Bright continued. "The solution was mRNA: a flexible, rapid-response technology that could be reprogrammed for any virus once its genetic sequence was known. That early investment laid the groundwork for the lightning-fast Covid-19 response four years later." Kennedy said in a post on X the time: "We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu," Kennedy said in a post on X. "We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." Newsweek has contacted the HHS, via online inquiry form, for a response to Bright's comments. File photo of an employee of the Bavarian Red Cross (BRK) preparing the BioNTech/Pfizer vaccine against the coronavirus SARS-CoV-2 for vaccination in a vaccination center, taken in Bavaria, Germany, in January 2021. File photo of an employee of the Bavarian Red Cross (BRK) preparing the BioNTech/Pfizer vaccine against the coronavirus SARS-CoV-2 for vaccination in a vaccination center, taken in Bavaria, Germany, in January 2021. AP What People Are Saying Former BARDA director Rick Bright said in his NYT op-ed: "Like every technology, mRNA has limitations. Vaccines meant to protect against respiratory infections, whether developed through mRNA or older technologies, are generally better at averting severe disease than preventing infection. It is a scientific challenge we can address with next-generation vaccines. The answer to limitations is improvement, not abandonment. "Political narratives about mRNA have fueled confusion, which leads to mistrust, yet the scientific evidence consistently shows that this technology is safe and effective and holds enormous potential for future vaccines and treatments." Children's Health Defense, an anti-vax nonprofit founded by Kennedy Jr. which focuses on childhood health epidemics, said in a post on X: "CHD applauds this most recent announcement to defund 22 mRNA vaccine projects under BARDA. While we believe that the mRNA shots on the market are unsafe and should be off the market, this is a welcome step in the right direction. The pandemic preparedness industry as it exists today is a threat to human welfare." What Happens Next HHS said it would shift funding toward other vaccine platforms but did not provide detailed timelines or specify which programs would receive redirected support. Scientific organizations, industry groups and public-health leaders said they would assess the impact and consider next steps, while some public-health advocates announced initiatives to defend vaccine science and provide public information.
Washington Post
3 days ago
- Washington Post
What I learned from astronaut Jim Lovell
Regarding the Aug. 9 front-page article 'Resourceful astronaut piloted treacherous Apollo 13 mission': Most people will remember James A. Lovell Jr. from Tom Hanks's portrayal of him in the movie 'Apollo 13,' but that is not what Lovell wanted to talk about in 2017 as I sat across from him; his wife, Marilyn; and their golden retriever, Toby. Instead, Lovell talked about Earth's exceptional place in the universe.
UPI
5 days ago
- UPI
Scientists sequence avian flu genome found in Antarctica
Penguins line the shore in South Georgia, Antarctica. A team of Chilean scientists has sequenced the first complete genomes of the H5N1 avian influenza virus found in birds in Antarctica. File Photo by L.A. Kelly Whybrow/Royal Nacy/EPA Aug. 15 (UPI) -- A team of Chilean scientists has sequenced the first complete genomes of the H5N1 avian influenza virus found in birds in Antarctica. The work, led by the University of Chile and the Chilean Antarctic Institute, was published in Emerging Infectious Diseases, a journal of the U.S. Centers for Disease Control and Prevention, marking a milestone in pathogen research on the frozen continent. The study, which included sequencing the virus in birds such as Antarctic skuas and terns, provides crucial information for understanding the evolution of H5N1 and its potential spread to other species. Sequencing a virus's genome is like reading its complete genetic code. In this case, genomic analysis of avian flu found in Antarctica showed the virus is part of the variant that has affected South America. "Sequencing and genetically characterizing this virus in Antarctic birds allows us to understand its behavior in an extreme, pristine and particularly vulnerable ecosystem," said Víctor Neira, a professor at the University of Chile's Faculty of Veterinary and Animal Sciences and a member of the research team. Specifically, the phylogenetic analysis showed a high genetic similarity to viruses detected in gulls and fur seals on South Georgia Island, confirming the existence of a viral migration route from South America to Antarctica. The finding underscores the need for constant global epidemiological surveillance and highlights the virus's risk of mutation, experts said. By infecting new species in a different environment, the virus could become more dangerous and pose a threat to human and animal health worldwide. According to the research team, its greatest contribution to Antarctic science is providing essential data on biodiversity and emerging risks in the region. In late 2023, H5N1 reached Antarctica for the first time, breaking the isolation that had kept the continent free of the virus. The first cases were recorded in skuas on South Georgia Island, and during 2024 and 2025, the virus spread to the Antarctic Peninsula and the Weddell Sea, affecting birds such as penguins, cormorants and gulls, as well as marine mammals including fur seals and elephant seals. Recent scientific expeditions detected nearly 200 infected animals from 13 species in more than 20 locations, confirming the outbreak has taken hold in the region and poses a serious threat to its fragile biodiversity.
